The stock of Humacyte Inc (NASDAQ:HUMA) last traded at $6.47, up 0.78% from the previous session.
HUMA stock price is now 78.41% away from the 50-day moving average and 101.87% away from the 200-day moving average. The market capitalization of the company currently stands at $770.45M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $6, H.C. Wainwright recently initiated with Buy rating for Humacyte Inc (NASDAQ: HUMA). On August 14, 2023, Piper Sandler Upgraded its previous ‘Underweight’ rating to ‘Neutral’ on the stock increasing its target price from $2.75 to quote $3.50, while ‘Cantor Fitzgerald’ rates the stock as ‘Overweight’
In other news, Binder Gordon M, Director bought 50,000 shares of the company’s stock on May 15 ’24. The stock was bought for $339,000 at an average price of $6.78. Upon completion of the transaction, the Director now directly owns 160,000 shares in the company, valued at $1.04 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 15 ’24, Director Binder Gordon M bought 50,000 shares of the business’s stock. A total of $328,500 was incurred on buying the stock at an average price of $6.57. This leaves the insider owning 50,000 shares of the company worth $0.32 million. A total of 24.06% of the company’s stock is owned by insiders.
During the past 12 months, Humacyte Inc has had a low of $1.96 and a high of $6.62. As of last week, the company has a debt-to-equity ratio of 0.71, a current ratio of 8.37, and a quick ratio of 8.37.
According to the Biotechnology Company, earnings per share came in at -0.22, inline with analysts’ expectations of -0.22. This compares to -$0.36 EPS in the same period last year. The company reported revenue of $26.58 million for the quarter, compared to $22.51 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 18.06 percent.
